Who are Triple antithrombotic therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Standard of Care - Double Oral.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/triple-antithrombotic-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Triple antithrombotic therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Triple antithrombotic therapy (Triple antithrombotic therapy) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antithrombotic combination therapy. Area: Cardiovascular.

marketed Antithrombotic combination therapy Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Triple antithrombotic therapy (Triple antithrombotic therapy) — The First Affiliated Hospital with Nanjing Medical University. Triple antithrombotic therapy combines three anticoagulant or antiplatelet agents to prevent blood clot formation through multiple complementary pathways.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Triple antithrombotic therapy TARGET	Triple antithrombotic therapy	The First Affiliated Hospital with Nanjing Medical University	marketed	Antithrombotic combination therapy
Standard of Care - Double Oral	Standard of Care - Double Oral	AOP Orphan Pharmaceuticals AG	marketed	Antithrombotic combination therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antithrombotic combination therapy class)

AOP Orphan Pharmaceuticals AG · 1 drug in this class
The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Triple antithrombotic therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/triple-antithrombotic-therapy. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab